Pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators
申请人:Pharmacia & Upjohn Company LLC
公开号:US07151109B2
公开(公告)日:2006-12-19
The present invention relates to novel pyrazolo[1,5-a]pyridine derivatives of general formula I:
that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.
PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS
申请人:Pharmacia & Upjohn Company LLC
公开号:EP1485384A1
公开(公告)日:2004-12-15
US7151109B2
申请人:——
公开号:US7151109B2
公开(公告)日:2006-12-19
[EN] PYRAZOLO(1,5-A)PYRIDINE DERIVATIVES AS NEUROTRANSMITTER MODULATORS<br/>[FR] DERIVES DE PYRAZOLO(1,5-A)PYRIDINE UTILISES EN TANT QUE MODULATEURS DU NEUROTRANSMETTEUR
申请人:UPJOHN CO
公开号:WO2003078435A1
公开(公告)日:2003-09-25
The present invention relates to novel pyrazolo[1,5-a]pyridine derivatives of general formula (I), that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.
Novel pyrazolo[1,5-a]pyridine derivatives and their use as neurotransmitter modulators
申请人:——
公开号:US20040002511A1
公开(公告)日:2004-01-01
The present invention relates to novel pyrazolo[1,5-a]pyridine derivatives of general formula I:
1
that bind with high affifnity to CRF
1
receptors, including human CRF
1
receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.